Siena Biotech forges discovery alliances with Singapore's science agency
This article was originally published in Scrip
Italy's Siena Biotech has entered into agreements with two units under Singapore's Agency for Science, Technology and Research (A*STAR) for collaborative research into novel small molecules and antibodies for various indications.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.